Form 4: Zentalis Pharmaceuticals Director David Johnson Granted Over 57,000 Restricted Stock Units

Zentalis Pharmaceuticals, Inc. Director David Michael Johnson was granted 57,603 restricted stock units (RSUs) as part of the company's non-employee director compensation program.

Summary

• David Michael Johnson, a Director of Zentalis Pharmaceuticals, Inc. (ZNTL), acquired 57,603 shares of common stock.
• The acquisition occurred on June 17, 2025, and was a grant of Restricted Stock Units (RSUs) with a transaction price of $0.
• These RSUs represent a contingent right to receive one share of common stock per unit.
• The RSUs are scheduled to vest on the earlier of June 17, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Johnson's continued service on the Issuer's Board of Directors through the vesting date.
• Following this transaction, David Michael Johnson beneficially owns a total of 250,421 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive due to increased director alignment with shareholder interests through equity compensation, which is a standard and expected practice.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The acquisition increases the director's direct beneficial ownership in the company, demonstrating continued commitment.

Future Outlook

The granted Restricted Stock Units are forward-looking, with vesting contingent on the director's continued service until June 17, 2026, or the next annual stockholders' meeting, whichever occurs first.

Industry Context

This Form 4 filing details a routine equity compensation grant to a non-employee director, a common practice across various industries, including pharmaceuticals, to attract and retain board talent and align their interests with shareholders.

Related Party Transactions

• The grant of Restricted Stock Units to David Michael Johnson, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors, executed under the Issuer's Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• Vesting of the 57,603 Restricted Stock Units on the earlier of June 17, 2026, or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Zentalis Pharmaceuticals, ZNTL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant